GlassScriptPhysician profile
Robert A Kiddy
NPI 1952539769
$27,402.52
in general payments reported to CMS, 2019-2025
35 companies · $2,567 in 2025
The $2,567 reported for 2025 was more than what 87% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,930 · 2020: $1,206 · 2021: $7,697 · 2022: $7,216 · 2023: $2,942 · 2024: $3,844 · 2025: $2,567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,046 · Travel and Lodging: $3,308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,045.70 |
| Travel and Lodging | $3,307.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $12,684.93 | 2019-2025 | Inbone, Infinity, Invision |
| Arthrex, INC. | $2,992.13 | 2021 | |
| Treace Medical Concepts, INC. | $2,707.96 | 2022-2025 | |
| Summit Surgical Corp. | $2,058.39 | 2019-2021 | |
| Anika Therapeutics, INC. | $1,592.19 | 2022-2024 | Integrity, Tactoset, Twist |
| Smith+Nephew, INC. | $1,376.99 | 2019-2025 | Grafix, Grafix Pl, Stravix Pl |
| Wright Medical Technology, INC. | $805.17 | 2019-2020 | |
| Fusion Orthopedics USA, LLC | $494.85 | 2025 | |
| Mimedx Group, INC. | $271.51 | 2025 | |
| Depuy Synthes Sales INC. | $249.26 | 2019-2021 | |
| Arthrosurface Incorporated | $228.21 | 2019-2025 | Toe Motiontm, Toemate |
| Pacira Pharmaceuticals Incorporated | $218.79 | 2021 | |
| Novartis Pharmaceuticals Corporation | $190.68 | 2022 | |
| Innovation Technologies INC | $159.93 | 2022-2024 | Irrisept |
| Trilliant Surgical LLC. | $133.98 | 2023 | Arsenal Ankle 10 Hole 1/3 Tubular Plate |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $124.18 | 2024 | |
| Glaxosmithkline, LLC. | $123.70 | 2019-2023 | Bexsero, Pediarix, Shingrix |
| Organogenesis INC. | $123.37 | 2024-2025 | Simplimax, Cygnus Dual |
| Paragon 28, INC. | $113.37 | 2020-2022 | |
| Ethicon US, LLC | $109.96 | 2022 | |
| Paratek Pharmaceuticals, INC. | $84.96 | 2024-2025 | Nuzyra |
| Sanofi Pasteur INC. | $79.99 | 2019-2022 | |
| Invictus Surgical Incorporated | $76.56 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.07 | 2020-2021 | |
| Medtronic, INC. | $55.52 | 2022 | |
| Rochester Medical Corporation | $47.58 | 2022 | |
| Arteriocyte Medical Systems, INC. | $46.67 | 2022 | |
| Novo Nordisk INC | $36.43 | 2022 | |
| Phadia US INC. | $33.01 | 2019-2022 | |
| Covidien LP | $27.79 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.00 | 2023 | Gattex |
| Shionogi INC | $18.37 | 2019 | |
| Xeris Pharmaceuticals, INC. | $14.46 | 2023 | Gvoke Hypopen |
| Hologic Sales and Service, LLC | $13.16 | 2019 | |
| Kci USA, INC. | $12.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Kiddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.